Institutional dossier
The documented history of Novartis: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2024-01-07 to 2025-02 · 0 undated
2 claims · 2 sources · 2 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: Pharmaceutical company; partner named in Isomorphic Labs' and Microsoft Research's texts.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2024Record year · 1 claims
- Isomorphic Labs announced on 7 January 2024 a strategic research collaboration with Novartis on small-molecule therapeutics against three undisclosed targets, stating an upfront payment of $37.5 million and eligibility for up to $1.2 billion in performance-based milestone payments.Isomorphic Labs → announced a partnership with → NovartisInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced · Stage: announced · exact USD 37,500,000 · transaction
Qualification and date notes
Announced terms as Isomorphic Labs states them; the milestone figure is an "up to" eligibility, not a payment. The release also states Novartis funding of select research costs, unquantified. No research outcome is implied.
Dated by the release.
2025Record year · 1 claims
- Isomorphic Labs' partnerships page (as served on 2026-10-30) states that Isomorphic and Novartis announced an expansion of their partnership in February 2025, adding up to three research programmes to the initial three targets.Isomorphic Labs → announced a partnership with → NovartisInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Rests on the company's later page, not on the February 2025 announcement; no terms of the expansion are stated there. "Up to three" programmes is the stated bound.
Month as stated by the later page; the February 2025 announcement itself was not retrieved.